celecoxib and Benign Neoplasms studies

Research Excerpts

Excerpt	Relevance	Reference
" antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity."	9.16	Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012)
"Standard dosing of the cyclooxygenase-2 inhibitor celecoxib slightly reduced perioperative cyclooxygenase activity during cancer surgery."	6.84	Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. ( Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S, 2017)
"Although the treatment of cancer cachexia, a multifactorial syndrome, is more likely to yield success with a multitargeted approach; in the present study, we were able to show that a treatment, such as celecoxib, addressing a single target, albeit very important as chronic inflammation, could have positive effects."	6.75	Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. ( Antoni, G; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010)
" Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route."	6.66	A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020)
" antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity."	5.16	Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012)
"The combination of celecoxib with docetaxel and irinotecan did not ameliorate irinotecan-induced diarrhea."	5.11	A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. ( Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP, 2005)
"Chronic inflammation is one of the main symptoms of cancer cachexia, and cyclooxygenase 2 inhibitors, such as celecoxib, may be beneficial in counteracting the major symptoms of this syndrome."	3.81	Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. ( Bi, Y; Han, M; Jiang, M; Xu, X; Zhang, Y, 2015)
" Two compounds 2c and 2e showed good anti-inflammatory activity which is comparable to the reference drug celecoxib in carrageenan-induced rat paw edema bioassay and found safe from the point of view of ulcer induction."	3.77	Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. ( Ahmad, S; Alam, MS; Bano, S; Javed, K; Rathish, IG; Singh, S, 2011)
"The selective COX-2 inhibitors NS-398, Celecoxib and Meloxicam and three human glioma cell lines (D384, U251 and U87) were used."	3.74	Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. ( Berg, Jv; Kuipers, GK; Lafleur, MV; Slotman, BJ; Sminia, P; Stoter, TR; Wedekind, LE, 2007)
"Inflammation is closely related to cancer prognosis."	3.01	Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and meta-analysis. ( Li, L; Qin, L; Zhang, Y, 2023)
"To determine the maximum tolerated dose, toxicities, and response of sirolimus combined with oral metronomic therapy in pediatric patients with recurrent and refractory solid and brain tumors."	2.94	A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. ( Cash, T; Goldsmith, KC; Katzenstein, HM; Kean, L; MacDonald, TJ; Qayed, M; Suessmuth, Y; Tanos, R; Tighiouart, M; Watkins, B; Wetmore, C, 2020)
"Standard dosing of the cyclooxygenase-2 inhibitor celecoxib slightly reduced perioperative cyclooxygenase activity during cancer surgery."	2.84	Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. ( Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S, 2017)
" Studies investigating optimal dosing for celecoxib and urea cream are recommended."	2.82	Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. ( Franco, PIG; Li, RK; Pandy, JGP, 2022)
"Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors."	2.79	A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014)
"Patients with advanced cancer received oral cyclophosphamide 50 mg o."	2.76	Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. ( Blann, AD; Han, C; Harris, AL; Khan, OA; Kirichek, O; Middleton, MR; Patil, M; Payne, MJ; Protheroe, AS; Talbot, DC; Taylor, M, 2011)
"Although the treatment of cancer cachexia, a multifactorial syndrome, is more likely to yield success with a multitargeted approach; in the present study, we were able to show that a treatment, such as celecoxib, addressing a single target, albeit very important as chronic inflammation, could have positive effects."	2.75	Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. ( Antoni, G; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010)
" Potential pharmacokinetic interactions and Topo-1 and DT-diaphorase (NQ01) gene expressions in peripheral-mononuclear cells were evaluated."	2.74	Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. ( Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y, 2009)
"Celecoxib was eliminated due to concerns of increased risk for cardiovascular toxicity, although no patients in this study had cardiac events."	2.73	A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. ( Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N, 2008)
" The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors."	2.73	Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. ( Chaudhary, U; Dunder, S; Green, M; Hayslip, J; Kraft, A; Meyer, M; Montero, AJ; Salzer, S; Sherman, C, 2007)
"Continuous dosing of the combination of capecitabine and celecoxib was well tolerated, produced antiangiogenic effects, and has antitumor activity."	2.73	Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. ( Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C, 2007)
"Celecoxib was given at 400 mg twice daily."	2.73	Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. ( Carroll, M; Frankel, P; Ruel, C; Smith-Powell, L; Synold, TW; Twardowski, PW; VanBalgooy, J, 2008)
"While cancer remains a significant global health problem, advances in cancer biology, deep understanding of its underlaying mechanism and identification of specific molecular targets allowed the development of new therapeutic options."	2.72	Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies. ( Abdeen, A; Barakat, AM; Elzoghby, AO; Khafaga, AF; Noreldin, AE; Sallam, MA; Shamma, RN, 2021)
"Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that can selectively target COX-2, suppress downstream pathways, and finally lead to anticancer potentiality."	2.66	MicroRNAs in the anticancer effects of celecoxib: A systematic review. ( Bagheri, A; Khazeei Tabari, MA; Mishan, MA; Zargari, M, 2020)
" Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route."	2.66	A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020)
"Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body."	2.61	Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019)
"Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2)."	2.49	Targeting apoptosis pathways by Celecoxib in cancer. ( Jendrossek, V, 2013)
"Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life."	2.49	Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. ( Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J, 2013)
"Celecoxib is a multifaceted drug with promising anticancer properties."	2.48	Celecoxib and Bcl-2: emerging possibilities for anticancer drug design. ( Payton-Stewart, F; Winfield, LL, 2012)
"Recently, their potential roles as cancer chemopreventive agents have been subject to intensive studies."	2.44	Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. ( Xiao, H; Yang, CS, 2008)
"Celecoxib (Celebrex) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain."	2.44	Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. ( Schönthal, AH, 2007)
" In theory, such compounds should be superior to celecoxib for antitumor purposes because they might reduce gastrointestinal and cardiovascular risks and the life-threatening side effects that appear during the long-term use of selective COX-2 inhibitors."	2.44	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. ( Chen, TC; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH, 2008)
"COX-2 is expressed in all stages of cancer, and in several cancers its overexpression is associated with poor prognosis."	2.42	Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? ( Choy, H; Milas, L, 2003)
"Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis."	2.42	Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. ( Abbasoglu, O; Akay, MT; Ercan, A; Kismet, K, 2004)
"Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events."	2.41	Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? ( Devière, J, 2002)
"Breast cancer (BC) was induced in BALB/c mice, and then they received DC vaccine treated with lipopolysaccharide (LPS-mDCs), LPS with a 5 μM dose of CXB (LPS/CXB5-mDCs) and LPS with a 10 μM dose of CXB (LPS/CXB10-mDCs)."	1.91	Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model. ( Ayoobi, F; Basirjafar, P; Gheitasi, M; Jafarzadeh, A; Khorramdelazad, H; Masoumi, J; Safdel, S; Taghipour, Z; Tavakoli, T; Yousefi, S; Zainodini, N; Zandvakili, R, 2023)
"Here, we studied the susceptibility of cancer cell spheroids, grown to the size of micrometastases, to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)."	1.56	Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. ( Beigl, TB; Budai, B; Cao, K; Fullstone, G; Hagenlocher, C; Kontermann, RE; Mack, A; Maichl, DS; Mürdter, TE; Pollak, N; Rehm, M; Scheurich, P; Schmid, JO; Stöhr, D; Tait, SWG, 2020)
" However, because of the complicated pharmacokinetics of combined drug formulations, the majority of combination strategies show severe adverse effects at high dosage and poor biodistribution in vivo."	1.48	Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy. ( Jin, X; Shi, L; Wu, C; Xu, L; Xue, B; Yang, J; Zhu, X, 2018)
"Celecoxib and ibuprofen treatment reversed the reduced production of glucose, pyruvate, lactate and urea from alanine as well as the reduced production of glucose from pyruvate and lactate in perfused liver from tumor-bearing rats."	1.42	Celecoxib and Ibuprofen Restore the ATP Content and the Gluconeogenesis Activity in the Liver of Walker-256 Tumor-Bearing Rats. ( Curi, R; de Morais, H; de Souza, CO; de Souza, HM; Hirabara, SM; Kurauti, MA; Rosa Neto, JC; Silva, Fde F, 2015)
"Up to 30% of cancer patients undergoing curative surgery develop local recurrences due to positive margins."	1.38	A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. ( Aliperti, LA; Cheng, G; Fridlender, ZG; Judy, B; Kapoor, V; Madajewski, B; Okusanya, O; Predina, JD; Quatromoni, J; Singhal, S, 2012)
"However, the basis for its cancer chemopreventive activity is not fully understood."	1.37	Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. ( Cao, W; Chen, S; Hao, C; Khuri, FR; Sun, SY; Yue, P, 2011)
"Celecoxib treatment down-regulated the expression of vascular endothelial growth factor receptor (VEGFR)-3 in stromal tissues by 73."	1.36	Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. ( Amano, H; Hayashi, I; Hosono, K; Ito, Y; Kamata, H; Kato, H; Kato, T; Kubo, H; Majima, M; Narumiya, S; Ogawa, Y; Sakagami, H; Sugimoto, Y; Suzuki, T; Watanabe, M, 2010)
"Cyclooxygenase-2 (COX-2) inhibitors are promising anticancer agents but their long-term use at high doses is associated with adverse cardiovascular events."	1.35	Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. ( He, Q; Huang, Y; Jin, W; Luo, X; Reddy, EP; Reddy, MV; Sheikh, MS, 2008)
"Thus thalidomide 400 mg was combined with celecoxib."	1.34	Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. ( Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D, 2007)
" However, the long-term use of NSAIDs, the cyclooxygenase (COX) inhibitors, may have significant adverse effects - primarily on the gastrointestinal (inhibiting COX-1) and cardiovascular (inhibiting COX-2) systems."	1.33	Genetic tools to tailor cancer prevention by NSAIDs. ( Bigler, J; Potter, JD; Ulrich, CM, 2006)
"COX-2 is overexpressed in cancer cells and has become a major target for cancer preventive drugs."	1.32	Does the release of arachidonic acid from cells play a role in cancer chemoprevention? ( Levine, L, 2003)

Research

Studies (111)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

27-Week Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.80)	18.2507
2000's	49 (44.14)	29.6817
2010's	44 (39.64)	24.3611
2020's	16 (14.41)	2.80

Authors	Studies
Knaus, EE	1
Innocenti, A	1
Scozzafava, A	1
Supuran, CT	1
Bano, S	1
Javed, K	2
Ahmad, S	1
Rathish, IG	1
Singh, S	2
Alam, MS	1
Lin, R	1
Elf, S	1
Shan, C	1
Kang, HB	1
Ji, Q	1
Zhou, L	1
Hitosugi, T	1
Zhang, L	1
Zhang, S	1
Seo, JH	1
Xie, J	1
Tucker, M	1
Gu, TL	1
Sudderth, J	1
Jiang, L	1
Mitsche, M	1
DeBerardinis, RJ	1
Wu, S	1
Li, Y	2
Mao, H	1
Chen, PR	1
Wang, D	1
Chen, GZ	1
Hurwitz, SJ	1
Lonial, S	1
Arellano, ML	1
Khoury, HJ	1
Khuri, FR	3
Lee, BH	1
Lei, Q	1
Brat, DJ	1
Ye, K	1
Boggon, TJ	1
He, C	1
Kang, S	1
Fan, J	1
Chen, J	1
Wang, ZC	1
Shen, FQ	1
Yang, MR	1
You, LX	1
Chen, LZ	1
Zhu, HL	1
Lu, YD	1
Kong, FL	1
Wang, MH	1
Kishore, N	1
Kumar, P	1
Shanker, K	1
Verma, AK	1
Peterková, L	1
Kmoníčková, E	1
Ruml, T	1
Rimpelová, S	1
Qin, X	1
Zhang, M	1
Zhao, Z	1
Du, Q	1
Li, Q	1
Jiang, Y	1
Xue, F	1
Luan, Y	1
Pandy, JGP	1
Franco, PIG	1
Li, RK	1
Raaijmakers, TK	1
van den Bijgaart, RJE	1
Scheffer, GJ	1
Ansems, M	1
Adema, GJ	1
Guo, Z	1
Sui, J	1
Wei, Q	1
Wei, C	1
Xiu, L	1
Zhu, R	1
Sun, Y	1
Hu, J	1
Li, JL	1
Kosaka, A	2
Yajima, Y	2
Yasuda, S	2
Komatsuda, H	2
Nagato, T	2
Oikawa, K	2
Kobayashi, H	2
Ohkuri, T	2
Li, L	2
Zhang, Y	2
Qin, L	1
Zandvakili, R	1
Basirjafar, P	1
Masoumi, J	1
Zainodini, N	1
Taghipour, Z	1
Khorramdelazad, H	1
Yousefi, S	1
Tavakoli, T	1
Safdel, S	1
Gheitasi, M	1
Ayoobi, F	1
Jafarzadeh, A	1
Saxena, P	1
Sharma, PK	1
Purohit, P	1
Qayed, M	1
Cash, T	1
Tighiouart, M	1
MacDonald, TJ	1
Goldsmith, KC	1
Tanos, R	1
Kean, L	1
Watkins, B	1
Suessmuth, Y	1
Wetmore, C	1
Katzenstein, HM	1
Stöhr, D	1
Schmid, JO	1
Beigl, TB	1
Mack, A	1
Maichl, DS	1
Cao, K	1
Budai, B	1
Fullstone, G	1
Kontermann, RE	1
Mürdter, TE	1
Tait, SWG	1
Hagenlocher, C	1
Pollak, N	1
Scheurich, P	1
Rehm, M	1
Mishan, MA	1
Khazeei Tabari, MA	1
Zargari, M	1
Bagheri, A	1
Wang, X	1
Wang, L	2
Xie, L	1
Xie, Z	1
Bui, D	1
Yin, T	1
Gao, S	1
Hu, M	1
Wen, B	1
Wei, YT	1
Mu, LL	1
Wen, GR	1
Zhao, K	1
Khafaga, AF	1
Shamma, RN	1
Abdeen, A	1
Barakat, AM	1
Noreldin, AE	1
Elzoghby, AO	1
Sallam, MA	1
Sobolewski, C	1
Legrand, N	1
Pramanik, R	1
Agarwala, S	1
Gupta, YK	1
Thulkar, S	1
Vishnubhatla, S	1
Batra, A	1
Dhawan, D	1
Bakhshi, S	1
Shi, L	1
Xu, L	1
Wu, C	1
Xue, B	1
Jin, X	1
Yang, J	1
Zhu, X	1
Tołoczko-Iwaniuk, N	1
Dziemiańczyk-Pakieła, D	1
Nowaszewska, BK	1
Celińska-Janowicz, K	1
Miltyk, W	1
Uram, Ł	1
Filipowicz, A	1
Misiorek, M	1
Pieńkowska, N	1
Markowicz, J	1
Wałajtys-Rode, E	1
Wołowiec, S	1
Heng-Maillard, MA	1
Verschuur, A	2
Aschero, A	1
Dabadie, A	1
Jouve, E	1
Chastagner, P	1
Leblond, P	1
Aerts, I	1
De Luca, B	1
André, N	4
Yaseen, S	1
Ovais, S	1
Bashir, R	1
Rathore, P	1
Samim, M	1
Nair, V	1
Brand, TM	1
Iida, M	1
Luthar, N	1
Starr, MM	1
Huppert, EJ	1
Wheeler, DL	1
Qin, W	1
Smith, C	1
Jensen, M	1
Holick, MF	1
Sauter, ER	1
Robison, NJ	1
Campigotto, F	1
Chi, SN	1
Manley, PE	1
Turner, CD	1
Zimmerman, MA	1
Chordas, CA	1
Werger, AM	1
Allen, JC	1
Goldman, S	1
Rubin, JB	1
Isakoff, MS	1
Pan, WJ	1
Khatib, ZA	1
Comito, MA	1
Bendel, AE	1
Pietrantonio, JB	1
Kondrat, L	1
Hubbs, SM	1
Neuberg, DS	1
Kieran, MW	1
Zhu, L	1
Ploessl, K	1
Kung, HF	1
Searle, EJ	1
Illidge, TM	1
Stratford, IJ	1
Cha, W	1
Park, SW	1
Kwon, TK	1
Hah, JH	1
Sung, MW	1
Booth, L	1
Roberts, JL	1
Cruickshanks, N	1
Tavallai, S	1
Webb, T	1
Samuel, P	1
Conley, A	1
Binion, B	1
Young, HF	1
Poklepovic, A	1
Spiegel, S	1
Dent, P	1
Xu, X	1
Jiang, M	1
Bi, Y	1
Han, M	1
Limasale, YD	1
Tezcaner, A	1
Özen, C	1
Keskin, D	1
Banerjee, S	1
de Souza, CO	1
Kurauti, MA	1
Silva, Fde F	1
de Morais, H	1
Curi, R	1
Hirabara, SM	1
Rosa Neto, JC	1
de Souza, HM	1
Wickström, M	1
Dyberg, C	1
Milosevic, J	1
Einvik, C	1
Calero, R	1
Sveinbjörnsson, B	1
Sandén, E	1
Darabi, A	1
Siesjö, P	1
Kool, M	1
Kogner, P	1
Baryawno, N	1
Johnsen, JI	1
Li, H	1
Jin, F	1
Jiang, K	1
Ji, S	1
Ni, Z	1
Chen, X	1
Hu, Z	1
Zhang, H	1
Liu, Y	1
Qin, Y	1
Zha, X	1
Hiller, JG	1
Sampurno, S	1
Millen, R	1
Kuruvilla, N	1
Ho, KM	1
Ramsay, R	1
Riedel, B	1
Xiao, H	1
Yang, CS	1
Rome, A	1
Coze, C	1
Padovani, L	2
Pasquier, E	2
Camoin, L	1
Gentet, JC	2
Xu, Y	1
Kolesar, JM	1
Schaaf, LJ	1
Drengler, R	1
Duan, W	2
Otterson, G	2
Shapiro, C	1
Kuhn, J	2
Villalona-Calero, MA	1
Lam, ET	1
O'Bryant, CL	1
Basche, M	1
Gustafson, DL	1
Serkova, N	1
Baron, A	1
Holden, SN	1
Dancey, J	1
Eckhardt, SG	1
Gore, L	1
Mantovani, G	3
Macciò, A	3
Madeddu, C	3
Serpe, R	3
Antoni, G	2
Massa, E	2
Dessì, M	2
Panzone, F	2
Kubo, H	1
Hosono, K	1
Suzuki, T	1
Ogawa, Y	1
Kato, H	1
Kamata, H	1
Ito, Y	2
Amano, H	1
Kato, T	1
Sakagami, H	1
Hayashi, I	1
Sugimoto, Y	1
Narumiya, S	1
Watanabe, M	1
Majima, M	1
Lane, R	1
Ferrario, A	1
Gomer, CJ	1
Meyskens, FL	1
McLaren, CE	1
Rezaie, F	1
Salimi, M	1
Ghahremani, MH	1
Vaziri, B	1
Jendrossek, V	1
Gravitz, L	1
Khan, OA	1
Blann, AD	1
Payne, MJ	1
Middleton, MR	1
Protheroe, AS	1
Talbot, DC	1
Taylor, M	1
Kirichek, O	1
Han, C	1
Patil, M	1
Harris, AL	1
Gao, M	1
Wang, M	1
Miller, KD	1
Zheng, QH	1
Chen, S	2
Cao, W	1
Yue, P	2
Hao, C	1
Sun, SY	2
Uddin, MJ	1
Crews, BC	1
Ghebreselasie, K	1
Huda, I	1
Kingsley, PJ	1
Ansari, MS	1
Tantawy, MN	1
Reese, J	1
Marnett, LJ	1
Cau, MC	1
Montaldo, L	1
Mela, Q	1
Mura, M	1
Astara, G	2
Tanca, FM	1
Abed, S	1
Orbach, D	1
Alla, CA	1
Scharovsky, OG	1
Matar, P	1
Rozados, VR	1
Rico, MJ	1
Zacarías Fluck, MF	1
Mainetti, LE	1
Fernández Zenóbi, MV	1
Roggero, EA	1
Gervasoni, SI	1
Rossa, A	1
Perroud, HA	1
Sánchez, AM	1
Celoria, GC	1
Font, MT	1
Lubet, RA	1
Clapper, ML	1
McCormick, DL	1
Pereira, MA	1
Chang, WC	1
Steele, VE	1
Fischer, SM	1
Juliana, MM	1
Grubbs, CJ	1
Winfield, LL	1
Payton-Stewart, F	1
Reid, J	1
Hughes, CM	1
Murray, LJ	1
Parsons, C	1
Cantwell, MM	1
Zapletalova, D	1
Deak, L	1
Kyr, M	1
Bajciova, V	2
Mudry, P	2
Dubska, L	1
Demlova, R	1
Pavelka, Z	2
Zitterbart, K	2
Skotakova, J	1
Husek, K	1
Martincekova, A	1
Mazanek, P	2
Kepak, T	2
Doubek, M	1
Kutnikova, L	1
Valik, D	2
Sterba, J	2
Predina, JD	1
Judy, B	1
Fridlender, ZG	1
Aliperti, LA	1
Madajewski, B	1
Kapoor, V	1
Cheng, G	1
Quatromoni, J	1
Okusanya, O	1
Singhal, S	1
Yamamoto, K	1
Asano, K	1
Matsukawa, N	1
Kim, S	1
Yamatodani, A	1
Devière, J	1
Levine, L	1
Grossman, HB	1
Burdan, F	1
Korobowicz, A	1
Haller, DG	1
Choy, H	1
Milas, L	2
Dannenberg, AJ	1
Subbaramaiah, K	1
Nakata, E	1
Mason, KA	1
Hunter, N	1
Husain, A	1
Raju, U	1
Liao, Z	1
Ang, KK	1
Kismet, K	1
Akay, MT	1
Abbasoglu, O	1
Ercan, A	1
Gehrmann, M	1
Brunner, M	1
Pfister, K	1
Reichle, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study[NCT01331135]	Phase 1	18 participants (Actual)	Interventional	2011-04-30	Completed
Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571]	Phase 3	108 participants (Actual)	Interventional	2013-10-31	Completed
Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500]	Phase 2	101 participants (Actual)	Interventional	2005-01-31	Completed
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408]	Phase 3	184 participants (Actual)	Interventional	2014-10-01	Completed
A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.[NCT01285817]	Phase 2	79 participants (Actual)	Interventional	2011-01-12	Completed
Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors[NCT00290680]	Phase 1	36 participants (Anticipated)	Interventional	2005-03-31	Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2002-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

27-Week Progression-Free Survival

Intervention	Probability (Number)
5-drug Metronomic Antiangiogenic Regimen	0.61

27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.

Therapy Completion Rate

Intervention	Probability (Number)
5-drug Metronomic Antiangiogenic Regimen	0.31

Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks

Best Response

Intervention	proportion of patients (Number)
5-drug Metronomic Antiangiogenic Regimen	.25

As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.

Response as Evaluated by Recurrence of Diseases

Intervention	participants (Number)
	Complete Response	Partial Response	Stable Disease	Progressive Disease	Not Evaluable
5-drug Metronomic Antiangiogenic Regimen	1	12	36	47	1

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Intervention	Participants (Number)
	Local Control Only	Local Control and Distant Metastasis	Distant Metastatsis Only	Secondary Primary - Site Unknown	Surgical Salvage
Recurrence	6	2	1	2	3

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Article	Year
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology, 2015, Volume: 17, Issue:11 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;	2015
Human disorders associated with inflammation and the evolving role of natural products to overcome. European journal of medicinal chemistry, 2019, Oct-01, Volume: 179 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular	2019
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective. Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5 Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Gene Regulatory Networks; Humans; Neoplasms; Prot	2020
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:11 Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Tr	2022
Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and meta-analysis. European journal of clinical investigation, 2023, Volume: 53, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib;	2023
A journey of celecoxib from pain to cancer. Prostaglandins & other lipid mediators, 2020, Volume: 147 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Inflam	2020
MicroRNAs in the anticancer effects of celecoxib: A systematic review. European journal of pharmacology, 2020, Sep-05, Volume: 882 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Humans; MicroRNA	2020
Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies. Nanomedicine (London, England), 2021, Volume: 16, Issue:19 Topics: Antineoplastic Agents; Celecoxib; Drug Repositioning; Humans; Nanomedicine; Neoplasms	2021
Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib. Biomolecules, 2021, 07-16, Volume: 11, Issue:7 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cyclooxygenase 2 Inhibitors; Humans; Neoplasm	2021
Celecoxib in Cancer Therapy and Prevention - Review. Current drug targets, 2019, Volume: 20, Issue:3 Topics: Animals; Apoptosis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Female; Humans	2019
Nuclear EGFR as a molecular target in cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 108, Issue:3 Topics: Animals; Celecoxib; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Neoplasms;	2013
Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)), 2014, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Celecoxib; Chemoradiotherapy; Clinical Trials as Topic; Cyclooxygenase 2 Inhi	2014
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Ce	2008
Targeting apoptosis pathways by Celecoxib in cancer. Cancer letters, 2013, May-28, Volume: 332, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Dr	2013
Celecoxib and Bcl-2: emerging possibilities for anticancer drug design. Future medicinal chemistry, 2012, Volume: 4, Issue:3 Topics: Animals; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Gene Expression	2012
Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliative medicine, 2013, Volume: 27, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Celecoxib; Cyclooxygenase 2 I	2013
Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? European journal of gastroenterology & hepatology, 2002, Volume: 14 Suppl 1 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Hu	2002
Selective COX-2 inhibitors as chemopreventive and therapeutic agents. Drugs of today (Barcelona, Spain : 1998), 2003, Volume: 39, Issue:3 Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox	2003
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:82 Topics: Alzheimer Disease; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito	2003
COX-2 inhibitors in oncology. Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12 Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxyg	2003
Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? Journal of the National Cancer Institute, 2003, Oct-01, Volume: 95, Issue:19 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Top	2003
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer cell, 2003, Volume: 4, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arachidonic Acid; Celecoxib; Cycloox	2003
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer detection and prevention, 2004, Volume: 28, Issue:2 Topics: Anticarcinogenic Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo	2004
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 7 Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase	2004
[Analgesic effects of cyclooxygenase 2 inhibitors]. Bulletin du cancer, 2004, Volume: 91 Spec No Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl	2004
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochemical pharmacology, 2004, Sep-15, Volume: 68, Issue:6 Topics: Animals; Antineoplastic Agents; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhib	2004
[Analgesic effects of cyclooxygenase 2 inhibitors]. Bulletin du cancer, 2004, Volume: 91 Suppl 2 Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; H	2004
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N	2006
Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2 Inh	2007
GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cellular signalling, 2008, Volume: 20, Issue:4 Topics: Animals; Antineoplastic Agents; beta Catenin; Celecoxib; Cell Cycle; Cell Differentiation; Curcumin;	2008
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2; Drug Evaluation, Preclinical; Humans; N	2008
Familiar drugs may prevent cancer. Postgraduate medical journal, 2001, Volume: 77, Issue:910 Topics: Angiotensin-Converting Enzyme Inhibitors; Anticarcinogenic Agents; Aspirin; Celecoxib; Cyclooxygenas	2001
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. QJM : monthly journal of the Association of Physicians, 2002, Volume: 95, Issue:5 Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C	2002

Article	Year
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatric blood & cancer, 2020, Volume: 67, Issue:4 Topics: Administration, Metronomic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla	2020
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial. JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9 Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P	2017
SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. Pediatric blood & cancer, 2019, Volume: 66, Issue:7 Topics: Administration, Metronomic; Adolescent; Adult; Celecoxib; Child; Child, Preschool; Disease-Free Surv	2019
Vitamin D favorably alters the cancer promoting prostaglandin cascade. Anticancer research, 2013, Volume: 33, Issue:9 Topics: Adult; Celecoxib; Cholecalciferol; Cyclooxygenase 2; Dinoprostone; Double-Blind Method; Female; Huma	2013
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric blood & cancer, 2014, Volume: 61, Issue:4 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi	2014
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2017, Volume: 64, Issue:5 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Follow-Up Studies; Humans; Inflammation; Male;	2017
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco	2009
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular cancer therapeutics, 2008, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C	2008
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. Journal of molecular medicine (Berlin, Germany), 2010, Volume: 88, Issue:1 Topics: Aged; Cachexia; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Middle Aged; Neoplasms; Pyra	2010
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. British journal of cancer, 2011, Jun-07, Volume: 104, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Antineoplastic Combined Chemotherapy Protocols; Cele	2011
Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clinical nutrition (Edinburgh, Scotland), 2012, Volume: 31, Issue:2 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Anorexia; Appetite; Cachexia; Carnitine; Celecoxib;	2012
Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget, 2011, Volume: 2, Issue:12 Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemot	2011
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp	2005
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:5 Topics: Adult; Aged; Anorexia; Ascorbic Acid; Cachexia; Carbocysteine; Celecoxib; Dietary Supplements; Docos	2006
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie, 2006, Volume: 29, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera	2006
A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. Journal of pediatric hematology/oncology, 2006, Volume: 28, Issue:11 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cel	2006
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC cancer, 2007, Dec-03, Volume: 7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cohort S	2007
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study. Onkologie, 2007, Volume: 30, Issue:12 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capec	2007
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer investigation, 2008, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Cyclophos	2008

Article	Year
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carb	2011
Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. European journal of medicinal chemistry, 2011, Volume: 46, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzene; Cell Line, Tumor; Cyclooxygenase	2011
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy. Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Drug Design; Humans; Matrix Metallopr	2018
A carrier-free photodynamic nanodrug to enable regulation of dendritic cells for boosting cancer immunotherapy. Acta biomaterialia, 2022, 07-15, Volume: 147 Topics: Celecoxib; Cell Line, Tumor; Dendritic Cells; Humans; Immunotherapy; Nanoparticles; Neoplasms	2022
NSAIDs affect dendritic cell cytokine production. PloS one, 2022, Volume: 17, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Ce	2022
GE11 peptide-decorated acidity-responsive micelles for improved drug delivery and enhanced combination therapy of metastatic breast cancer. Journal of materials chemistry. B, 2022, 11-16, Volume: 10, Issue:44 Topics: Animals; Celecoxib; Cell Line, Tumor; Doxorubicin; Mice; Micelles; Neoplasms; Polymers	2022
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 International journal of cancer, 2023, 04-15, Volume: 152, Issue:8 Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cyclooxygenase 2 Inhibitors; Glucose; Immunotherapy;	2023
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 International journal of cancer, 2023, 04-15, Volume: 152, Issue:8 Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cyclooxygenase 2 Inhibitors; Glucose; Immunotherapy;	2023
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 International journal of cancer, 2023, 04-15, Volume: 152, Issue:8 Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cyclooxygenase 2 Inhibitors; Glucose; Immunotherapy;	2023
Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 International journal of cancer, 2023, 04-15, Volume: 152, Issue:8 Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cyclooxygenase 2 Inhibitors; Glucose; Immunotherapy;	2023
Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model. Advances in medical sciences, 2023, Volume: 68, Issue:1 Topics: Animals; Celecoxib; Dendritic Cells; Forkhead Transcription Factors; Granzymes; Immunity, Cellular;	2023
Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell death and differentiation, 2020, Volume: 27, Issue:11 Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Huma	2020
Design and Synthesis of a Novel NIR Celecoxib-Based Fluorescent Probe for Cyclooxygenase-2 Targeted Bioimaging in Tumor Cells. Molecules (Basel, Switzerland), 2020, Sep-04, Volume: 25, Issue:18 Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors;	2020
The molecular mechanisms of celecoxib in tumor development. Medicine, 2020, Oct-02, Volume: 99, Issue:40 Topics: Apoptosis; Autophagy; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug	2020
Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy. ACS applied materials & interfaces, 2018, Mar-14, Volume: 10, Issue:10 Topics: Albumins; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Hu	2018
Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Nov-01, Volume: 124 Topics: Antineoplastic Agents; Biotinylation; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 2 Inhibito	2018
Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents. Archiv der Pharmazie, 2013, Volume: 346, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzenesulfonamides; Celecoxib; Cell Line,	2013
Chemistry. Expanding the scope of fluorine tags for PET imaging. Science (New York, N.Y.), 2013, Oct-25, Volume: 342, Issue:6157 Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioi	2013
Endoplasmic reticulum stress response as a possible mechanism of cyclooxygenase-2-independent anticancer effect of celecoxib. Anticancer research, 2014, Volume: 34, Issue:4 Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxyge	2014
PDE5 inhibitors enhance celecoxib killing in multiple tumor types. Journal of cellular physiology, 2015, Volume: 230, Issue:5 Topics: Animals; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum St	2015
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. Molecular medicine reports, 2015, Volume: 11, Issue:1 Topics: Anemia; Animals; Antibodies, Monoclonal; Body Weight; Cachexia; Celecoxib; Cell Line, Tumor; Cycloox	2015
Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. International journal of pharmaceutics, 2015, Feb-20, Volume: 479, Issue:2 Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Delivery Systems; E	2015
Celecoxib and Ibuprofen Restore the ATP Content and the Gluconeogenesis Activity in the Liver of Walker-256 Tumor-Bearing Rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 36, Issue:4 Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Gluconeogenesis	2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nature communications, 2015, Nov-25, Volume: 6 Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele	2015
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency. Oncotarget, 2016, May-10, Volume: 7, Issue:19 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Celecoxib; Cell Proliferati	2016
Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clinical therapeutics, 2008, Volume: 30, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cycl	2008
Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:2 Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation, Neopl	2010
A protocol for labrador retrievers? Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707 Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Hormonal; Celecoxib; Cyclooxygenase 2 Inhibit	2009
Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. Methods in molecular biology (Clifton, N.J.), 2010, Volume: 635 Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Combined Modality Therapy; Cy	2010
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? Journal of the National Cancer Institute, 2010, Dec-15, Volume: 102, Issue:24 Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell;	2010
Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line. Molecular bioSystems, 2011, Volume: 7, Issue:4 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Chemoprevention; Cyclooxygenase 2 Inhib	2011
Chemoprevention: First line of defence. Nature, 2011, Mar-24, Volume: 471, Issue:7339 Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I	2011
Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer. European journal of medicinal chemistry, 2011, Volume: 46, Issue:9 Topics: Carbon Radioisotopes; Celecoxib; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure	2011
Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer research, 2011, Oct-01, Volume: 71, Issue:19 Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Celecoxib; Cell Line, Tumor; Cyclooxyge	2011
Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:10 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Halogenation; Humans; Indomethacin; Inflamm	2011
[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research]. Medicina, 2012, Volume: 72, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Celecoxib; Cl	2012
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncology reports, 2012, Volume: 27, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co	2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology, 2012, Volume: 82, Issue:5 Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chem	2012
A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer biology & therapy, 2012, Volume: 13, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Chemotherapy, A	2012
Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats. Toxicology, 2012, Dec-16, Volume: 302, Issue:2-3 Topics: Animals; Anorexia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Docetaxel; Hypothalamus	2012
Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Arachidonic Acid; Catechi	2003
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. International journal of radiation oncology, biology, physics, 2004, Feb-01, Volume: 58, Issue:2 Topics: Animals; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo	2004
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis;	2004
Despite positive studies, popularity of chemoprevention drugs increasing slowly. Journal of the National Cancer Institute, 2004, Oct-06, Volume: 96, Issue:19 Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarci	2004
Vioxx withdrawal alarms cancer prevention researchers. Journal of the National Cancer Institute, 2004, Dec-01, Volume: 96, Issue:23 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyc	2004
Clinical trials. Nail-biting time for trials of COX-2 drugs. Science (New York, N.Y.), 2004, Dec-03, Volume: 306, Issue:5702 Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical	2004
COX-2 inhibitors: cancer prevention or cardiovascular risk? The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy	2005
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Ce	2005
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer research, 2005, Oct-15, Volume: 65, Issue:20 Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cyc	2005
[Natural substances and pharmaceutical preparations can prevent cancer. Chemoprevention instead of chemotherapy]. MMW Fortschritte der Medizin, 2005, Oct-27, Volume: 147, Issue:43 Topics: Celecoxib; Cyclooxygenase Inhibitors; Female; Fruit; Humans; Male; Neoplasms; Pyrazoles; Risk Factor	2005
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemother	2007
Genetic tools to tailor cancer prevention by NSAIDs. Discovery medicine, 2006, Volume: 6, Issue:32 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 1	2006
Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. Journal of biomedical science, 2007, Volume: 14, Issue:5 Topics: Celecoxib; Cell Hypoxia; Cell Line, Tumor; Cobalt; Cyclooxygenase 2 Inhibitors; Endoplasmic Reticulu	2007
CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand Molecular pharmacology, 2007, Volume: 72, Issue:5 Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD	2007
Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. International journal of radiation biology, 2007, Volume: 83, Issue:10 Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose	2007
Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene, 2008, Apr-17, Volume: 27, Issue:18 Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Screening Assays, Antitumo	2008
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Molecular cancer, 2008, May-16, Volume: 7 Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inh	2008
Atorvastatin and celecoxib: a future role in cancer chemoprevention. International journal of cancer, 2008, Aug-01, Volume: 123, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; A	2008
Cancer and arthritis share underlying processes. Journal of the National Cancer Institute, 1998, Jun-03, Volume: 90, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo	1998
Early trials probe COX-2 inhibitors' cancer-fighting potential. Journal of the National Cancer Institute, 1999, Jul-21, Volume: 91, Issue:14 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc	1999
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer research, 2000, Mar-01, Volume: 60, Issue:5 Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy	2000
COX-2 in cancer--a player that's defining the rules. Journal of the National Cancer Institute, 2002, Apr-17, Volume: 94, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Humans; Isoenzymes; Me	2002

celecoxib and Benign Neoplasms